Clinical Research Center for Rare Diseases Aldo & Cele Dacco

Bergamo, Italy

Clinical Research Center for Rare Diseases Aldo & Cele Dacco

Bergamo, Italy
SEARCH FILTERS
Time filter
Source Type

Perico N.,Clinical Research Center for Rare Diseases Aldo & Cele Dacco | Ruggenenti P.,Clinical Research Center for Rare Diseases Aldo & Cele Dacco | Remuzzi G.,Clinical Research Center for Rare Diseases Aldo & Cele Dacco | Remuzzi G.,University of Milan
Current Opinion in Pharmacology | Year: 2017

Most chronic nephropathies progress relentlessly to end-stage kidney disease. Research in animals and humans has helped our understanding of the mechanisms of chronic kidney disease progression. Current therapeutic strategies to prevent or revert renal disease progression focus on reduction of urinary protein excretion and blood pressure control. Blockade of the renin-angiotensin system (RAS) with angiotensin-converting enzyme inhibitors and/or angiotensin II type 1 receptor blockers is the most effective treatment to achieve these purposes in non-diabetic and diabetic proteinuric renal diseases. For those individuals in which nephroprotection by RAS blockade is only partial, sodium–glucose linked cotransporter-2 (SGLT2) inhibitors could be a promising new class of drugs to provide further renoprotective benefit when added on to RAS blockers. © 2017 Elsevier Ltd

Loading Clinical Research Center for Rare Diseases Aldo & Cele Dacco collaborators
Loading Clinical Research Center for Rare Diseases Aldo & Cele Dacco collaborators